Get started
Aditxt, Inc.Aditxt, Inc.Aditxt, Inc.

Aditxt, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

ADTX trade ideas

ADTX MonthlyADTX is in a falling downtrend, as shown in the declining parallel channel. It had an all time high of $19,160, and a low of $7.34. There has been 5 huge monthly green candles in ADTXs history. (Noted with orange circles) These candles may have caused FOMO for impatient investors. These 5 candles had increases of 79%, 12%, 23%, 17% and 245%. Each time these monthly candles went parabolic, it got rejected by resistance (yellow lines,) and continued stair stepping down to a lower low. This stock has 38 monthly candles in its entire existence. Thirty of them were red months, and only 8 were green months. As of one trading day in September, it is a green candle.
NASDAQ:ADTX
by babychester
8
$ADTX A Reverse Split Play Heating UpAditxt, Inc. (NASDAQ: ADTX) is a promising biotech company with a main focus of developing technologies that improve the health of the immune system. While the stock has been plunging for a while now, ADTX stock is grabbing investors attention in the meantime after the company effected a reverse split. Considering that reverse split plays are gaining more interest from investors, ADTX climbed by as much as 139%. As the company is set to trade on a post-split basis today, ADTX could be one to watch this week as it could continue soaring. ADTX Fundamentals AditxtScore Through its proprietary monitoring technology – Aditxtscore – ADTX aims to provide patients with a thorough profile of their immune system by monitoring reactions to different viruses, bacteria, allergens, as well as transplanted organs. After monitoring the immune system’s reactions, AditxtScore can anticipate attacks on the body and determine potential responses. As a result, the immune system would be able to manage or neutralize the pathogen more effectively. Since this platform could revolutionize the treatment of several diseases, ADTX stock could be one to invest in for the long-term. Currently, ADTX is developing AditxtScore for treating type 1 diabetes. This could be achieved through AditxtScore’s ability to detect auto-antibodies early. Following this, the platform monitors the progression of the disease and its response to therapy. By following this mechanism, AditxtScore has the potential to be applied in treating diseases affecting the immune system, bones and joints, brain, cardiometabolic, thyroid, as well as hormone imbalances. Given the potential of treating such diseases, ADTX has the potential to process more than 10 million Aditxtscores annually which could provide the company with significant revenues in the future. Adimune As well as AditxtScore, ADTX is developing another technology – Adimune – to modulate the immune system and address autoimmunity, organ rejection, and allergies. Considering this technology’s long-term potential, ADTX protected this technology by 7 patent families in the US and across the world. Out of these patents, 8 are based in the US and 4 additional patents are pending applications. Meanwhile, Adimune has 86 foreign patents and applied for an additional 14 patents globally. With this in mind, these patents are categorized into 3 groups for autoimmune diseases and type 1 diabetes, prevention of immune activation, and delivery systems for antigens. Through these patents, ADTX has the potential to emerge as a global leader in treating such diseases. In the meantime, ADTX is studying the possibility of utilizing Adimune in treating Psoriasis which is caused when the immune system attacks skin cells. ADTX is looking to use Adimune in preventing these attacks and dealing with the causes of skin cell build-ups. In a 10-day study, Adimune was able to reduce skin thickening and scaling by 69% and 38% respectively. Moreover, ADTX is studying Adimune’s ability to treat type 1 diabetes by stopping the immune system malfunction to allow for the production of insulin. If this approach is successful, Adimune could be the first permanent cure for type 1 diabetes. With this in mind, Adimune already showed encouraging results in initial trials as it successfully restored insulin production and reversed hyperglycemia. ADTX is also studying Adimune’s ability to cure skin allografts which result from skin grafting to cover wounds. Since grafting is not a permanent solution to these cases, ADTX is aiming to utilize Adimune in increasing the graft’s longevity to improve patients’ quality of life and reduce the number of required surgeries in the future. Considering Adimune’s potential in treating all of these diseases, ADTX intends to move forward with clinical trials for treating psoriasis, diabetes, and skin allografts in 2023 after completing pre-clinical studies this year. In light of this, ADTX stock could be well-positioned to soar on more updates regarding clinical trials. Cellvera Looking to generate revenues to aid it in growing its business, ADTX entered into a revenue sharing agreement with Cellvera Global Holdings LLC, formerly AiPharma Global Holdings LLC. With this in mind, ADTX has agreed to acquire Cellvera, however, the acquisition remains in the due diligence stage. Despite this, ADTX could be able to realize more revenues in the lead up to the acquisition thanks to this agreement as it allows ADTX to receive up to 10% of net sales up to a maximum of $30 million. In this way, ADTX could be well-positioned for financial growth since Cellvera holds exclusive global rights to a broad spectrum oral antiviral drug targeting Covid-19 and 11 other diseases. As the demand for such antivirals is high at the moment, ADTX could receive a much needed boost to its financials from this agreement. Reverse Split Meanwhile, ADTX stock is receiving investors’ attention after sharing its plans to effect a 1 for 50 reverse split to regain compliance with the NASDAQ listing rules. As this reverse split would see the company have an OS of only 1.1 million shares, ADTX stock has been emerging as a potential reverse split runner as these plays have been the hottest in the market lately. With this in mind, many investors are bullish ADTX stock could witness a run-up similar to ShiftPixy, Inc. (NASDAQ: PIXY) and NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO). For this reason, ADTX stock is one to watch this week in case it further runs. ADTX Financials According to its Q2 report, ADTX has $10 million in assets including $803.9 thousand in cash. However, this is a decline from the company’s assets at December 31, 2021 where the company reported $16.6 million in assets and $7.8 million in cash. Meanwhile, liabilities increased from Q4 to $9.3 million compared to $6.4 million. In terms of revenues, ADTX reported $214.7 thousand in Q2 making its revenues for the first half of 2022 $424.9 thousand after not realizing any revenues last year. However, the company incurred $5.8 million in operating costs – leading to a net loss of $5.8 million. Considering that the company remains in its early growth stages, ADTX could be poised for significant revenue growth when its treatments are brought into the market. Technical Analysis ADTX stock is currently trading at $18.4 and has supports near 16.68, 12.35, and 6.25. Meanwhile, the stock shows resistances near 21.9, 26.07, and 30.56. With the stock running past $29 in pre-market, ADTX could test its resistance near $30 with high momentum. However, investors should be wary that the stock already ran nearly 140% leading up to the reverse split which could see the stock drop due to investors selling the news. For this reason, bullish investors could find good entry points on retests of supports if the supports hold. As reverse split plays are becoming more popular lately, accumulation is trending upwards and the MACD is bullish to the upside. However, the RSI is at 85 indicating that ADTX stock is overbought. In light of this, ADTX could be poised to drop as the RSI regulates which could present good entries for the stock. Following its reverse split, ADTX has an OS around 1.1 million and a float near 1 million. ADTX Forecast By utilizing its technology platforms, ADTX has significant growth potential when its treatments are introduced to the market as they could revolutionize treating diabetes, Psoriasis, and skin allografts. However, since these treatments are yet to start clinical trials, any future growth could take years to materialize. With this in mind, ADTX stock like other biotech stocks move on binary events like FDA approvals and clinical trial news. Based on this, ADTX could soar soon as it plans to start clinical trials for its treatments in 2023. Meanwhile, ADTX stock is becoming an attractive investment in the short-term following its reverse split. Considering the growing popularity of reverse split plays, ADTX stock is one to watch this week for a continuation. However, investors should be wary that the stock could easily drop due to selling the news.
NASDAQ:ADTX
by Penny_Stocks_Today
2
My recommended portfolio for 1-5 February 2021First of all I would like to thanks all my supportive followers who support me on TradingView by likes, comments and transferring coins. After 3 successful weeks in January, we are heading to February with a hazy market outlook. My recommended portfolios of 25 stocks made 38.51% (compound / volume weighted) 4.37% , 18.32%, and 12.17% in 3 weeks of a month which all major indexes were NEGATIVE. (SPX -1.11%, NDX +0.29% and DJI -2.04), In January ARKK the most famous managed ETF made 10.4%. I also published many sporadic analysis, 26 of which experienced +100-700% gain In January 2021 with only 19 trading days..! As always we should try our best and makes our strategy better and better, so this will be my recommended portfolio of 25 stocks for 1-5 of February: 1- ADTX @ 3.73 2- AI @ 139.60 3- AKRO @ 29.42 4- CRM @ 225.56 5- EBON @ 5.13 6- EDTK @ 3.26 7- EYES @ 2.16 8- FSR @ 15.03 9- GM @ 50.68 10- GNUS @ 1.78 11- GRPN @ 34.17 12- GSV @ 0.7093 13- INTC @ 55.51 14- MARA @ 20.74 15- METX @ 2.03 16- MRIN @ 2.16 17- MTC @ 2.07 18- OPTT @ 4.01 19- RIOT @ 20.52 20- SNOW @ 272.45 21- THMO @ 3.41 22- VLDR @ 21.74 23- VRM @ 36.83 24- WISA @ 3.34 25- WORX @ 2.03 This is just my technical view, neither a fundamental comment,nor a recommendation to trade..! Please review my track record and calculate the odds for yourself..! Don't forget to like, comment, and Follow to encourage me to continue this. You can send TradingView coins to support me publishing high quality ideas..! Stay tuned great live stream and quality content videos coming soon..! I would appreciate if you share my analysis on your own social media with your friends and beloved ones. Moshkelgosha
NASDAQ:ADTXLong
by Moshkelgosha
37
This is just the Tip of the iceberg..!What does really make a company so special and extraordinary??? Without any doubt special and extraordinary people,like Steve Jobs, Elon Musk, Bill Gates, Jack Ma, and... What makes ADITX special is the story behind this company which started almost 40 years ago. If you check the founders of the company on TradingView, you will see the names of Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna. I would like to write about Leonard L. Bailey, and his incredible story. Leonard Lee Bailey (1942–2019) was an American surgeon who garnered international media attention in 1984 for transplanting a baboon’s heart into a human infant. In 1984, in a desperate attempt to save the life of a baby girl, Dr. Bailey performed the first cross-species infant heart transplant. Born three weeks early, Stephanie Fae (known as Baby Fae) was diagnosed with 100% lethal hypoplastic left heart syndrome.  Dr. Bailey, having seen too many newborns succumb to this condition, was prepared. For years, he had been performing research through experimental transplantation in sheep, goats and baboons. By the time Baby Fae was born, he had performed over 200 of these procedures. With no time and no other options, Dr. Bailey did what he knew he had to — what he knew could save this girl’s life. As media members and animal rights activists gathered outside the building, Bailey and the medical staff focused all their energy on the little girl. Baby Fae survived the transplant, which provided her a new, healthy and, against all odds, beating baboon heart. Though the transplant gave her a little extra time, Baby Fae tragically passed away 21 days later. She became the longest-living recipient of a cross-species heart. The next year, in 1985, Dr. Bailey once again met a patient in need of a new heart. This time, though, a suitable donor heart was available. Using the lessons he learned with Baby Fae, Dr. Bailey performed the first successful human-to-human heart transplant on an infant. Little Eddie Anguiano (known as Baby Moses) not only survived, but continues to thrive to this day at 35 years old. Eddie is the longest-living recipient of an infant heart transplant — that same heart still beats in his chest.(Loma Linda university website) What he did 37 years ago looks like Sci-fi movies today..! But what makes ADITX special doesn’t end here, ADITX starts generating revenue through its contract with Todos medical just 7 months after its IPO in July 30th 2020, which is very unusual for a biotechnology company. Usually, biotechnology companies tend to burning cash for many years before generating any revenue..! Yet it’s a normal, because developing a medical product and getting all the FDA approvals is a long process. I will not be shocked if soon Cathie Wood (ARK Invest) talks about this company and buy its stocks, because what ADITX is doing is in the field of their interest “Genomic field”..! Ark invest actually count heavily on genomic fields for the next decade..! Having reviewed this incredible story, I will review the technical reasons that I put this in my recommended portfolio in a video soon..! Stay tuned great live stream and quality content videos coming soon..! Don't forget to like, comment, and Follow to encourage me to continue this. You can even send TradingView coins to support me publishing high quality ideas..!
NASDAQ:ADTXLong
by Moshkelgosha
10
AditxtScore™ Immune Monitoring Service Operational on February 1AditxtScore™ Immune Monitoring Service Will be Operational on February 1st Company Plans to Offer Service through Channel Partners The initial application of the platform will be AditxtScore™ for COVID-19 which has been designed to provide a more complete assessment of an individual’s infection and immunity status with respect to the SARS-CoV-2 virus. We’re currently in discussions with labs, hospitals and other channel partners around the world interested in incorporating AditxtScore™ into their offerings. finance.yahoo.com
NASDAQ:ADTX
by AlenCiken
ADTX Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $ADTX - ADiTx Therapeutics, Inc. - Common Stock Initial Alert Price: $2.1 Price High: $6.73 % Gains/Losses: 220.48% (+201% More Than Expected) Potential Stop Loss: $6.3935 ADTX hit $6.73 providing a 180.42% Return on Investment from our initial trade alert on December 22nd, 2020 due to the release date being set for the AditxtScore Platform Immune Monitoring Platform on Feb. 1st, 2020. The initial application of the platform will be AditxtScore for Covid-19, which has been designed to provide a more complete assessment of an individual's infection and immunity status with respect to the SARS-CoV-2 virus. We're currently seeing some healthy pullback but expect this to continue to run as the stock is showing signs of reversing on the lower timeframes as of this message. Keep a close on eye on this moving forward and look forward for our Exit Strategy Alert if we see one fit for this trade at this time. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
NASDAQ:ADTXLong
by MyMIWallet
4
$ADTX Swing TradeThere are several catalysts awaiting $ADTX this year, with pending FDA approval for a psoriasis treatment being one major one. On a purely technical play, however, the TTBB Swing Trading Breakout Line indicates that a swing trade may be setting up at the 2.14 price level. I will await entry to when this breaks the previous week's high of 2.25 as confirmation of a bullish breakthrough. Should any pending news catalysts come through positively, a target of 3.32, a previously set high in December is possible and will be my target exit. NASDAQ:ADTX
NASDAQ:ADTXLong
by Vencero_JG
2
ADTX Breakout Stock AlertBREAKOUT STOCK ALERT $ADTX - ADiTx Therapeutics, Inc. - Common Stock Initial Alert Price: $2.10 Potential Price: $2.50 Potential Gains: 19% Stop Loss Limit: $2 Looking for a $2.50 Swing Trade on ADTX as it completes consolidation from it's most recent $3.31 Breakout. ADTX just recently signed a Distribution Agreement with Todos Medical Ltd. for Adixtx Score for COVID-19 Immune Monitoring Service, which is planned to be available in January 2021. The two companies will work together in collecting blood samples and processing those samples to determine the efficacy of the vaccines used on individual's and the effects of their immune profile. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today Follow for more trade alerts and information & egister your account for Instant Alerts by clicking the link in our signature.
NASDAQ:ADTXLong
by MyMIWallet
$ADTX is gonna fall todayPupm&Dump trading strategy idea. $ADTX is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,19; stop-loss — $2,31; take-profit — $2,07; Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:ADTXShort
by KozakHlib